Laboratory monitoring of heparin: Challenges and opportunities

Laboratory Medicine

Volumn 38, Issue 8, 2007, Pages 499-502

  Winkler, Anne M ^a   Sheppard, Chelsea A ^a   Fantz, Corinne R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ANTICOAGULANT THERAPY; BLEEDING; CHEMOPROPHYLAXIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; HEMOSTASIS; HEPARINIZATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; REVIEW; THROMBOSIS;

EID: 34547623042     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/B0XGVJYD9AHWPTF4     Document Type: Review

References (15)

1. Li W, Johnson DJ, Esmon, CT, et al. Structure of the antithrombin- thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol. 2004;11:857-862.
2. Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133:19-34.
3. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol. 1997;108:662-668.
4. Wessler S, Morris LE. Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis. Circulation. 1955;12:553-556.
5. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl J Med. 1972;287:324-327.
6. Bates SM, Weitz JI, Johnston M, et al. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range of unfractionated heparin. Arch Intern Med. 2001;161:385-391.
7. Valenstein PN, Walsh MK, Meier F. Heparin monitoring and patient safety: A College of American Pathologists Q-probes study of 3,431 patients at 140 institutions. Arch Pathol Lab Med. 2004;128:397-402.
8. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
9. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost. 2006;96:547-552.
10. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
11. McGlasson DL, Kaczor DA, Krasuski RA, et al. Effects of pre-analytical variables on the anti-activated factot X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin. Blood Coagul Fibrinolysis. 2005;16:173-176.
12. Levine MN, Hirsh J, Gent M et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
13. Rosborough TK. Monitoring unfractionated heparin therapy with anti-factor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacotherapy. 1999;19:760-766.
14. Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy. 2004;24:713-719.
15. Rosborough TK. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial anti-factor Xa activity better than patient weight alone. Pharmacotherapy. 1998;18:1217-1223.